Noven Pharmaceuticals cited for drug patch's faulty release liners
This article was originally published in The Gold Sheet
Executive SummaryFDA issued a warning letter on Jan. 4 to Noven Pharmaceuticals of Miami, Fla, where the firm manufacturers its Daytrana (methylphenidate) patch for attention deficit/hyperactivity disorder. During inspections in June and July 2007, FDA observed a failure to establish scientifically sound and appropriate specifications, standards and test procedure designed to assure that the drug products conform to appropriate standards of identity, strength, quality and purity. For example, a liner release force specification had not been established for the patch at the time of the inspection
You may also be interested in...
Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, talks in a wide-ranging interview about the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.
Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.